---
title: "CRMD.US (CRMD.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/CRMD.US/news.md"
symbol: "CRMD.US"
name: "CRMD.US"
parent: "https://longbridge.com/zh-CN/quote/CRMD.US.md"
datetime: "2026-03-15T19:51:25.508Z"
locales:
  - [en](https://longbridge.com/en/quote/CRMD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CRMD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CRMD.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/CRMD.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/CRMD.US/news.md)


# CRMD.US (CRMD.US) — 相关新闻

### [CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference](https://longbridge.com/zh-CN/news/279132884.md)
*2026-03-14T21:22:10.000Z*
> CorMedix (NASDAQ:CRMD) executives presented at the Citizens Life Sciences Conference, focusing on expanding their pipeli

### [CorMed reaffirming FY2027 DefenCath sales guidance of $100M–$140M, updates investor presentation](https://longbridge.com/zh-CN/news/278175006.md)
*2026-03-06T22:13:00.000Z*
> CorMed reaffirmed its FY2027 DefenCath sales guidance of $100M–$140M, correcting a previous reference of $100M–$125M. Th

### [CorMedix stock drops after earnings: is this dip a buy before key catalyst?](https://longbridge.com/zh-CN/news/278056003.md)
*2026-03-06T08:32:17.000Z*
> CorMedix (NASDAQ: CRMD) saw its stock drop on March 5th after reporting a significant swing to profitability but reaffir

### [CorMedix Q4 Revenue Improves; Reaffirms FY26 Outlook; Plans To Report Phase III REZZAYO Data In Q2](https://longbridge.com/zh-CN/news/278052181.md)
*2026-03-06T08:10:58.000Z*
> CorMedix Inc. (CRMD) reported Q4 2025 revenue growth, with net income of $14.02 million and total revenue of $128.62 mil

### [Sector Update: Health Care Stocks Decline Late Afternoon](https://longbridge.com/zh-CN/news/277986614.md)
*2026-03-05T20:51:00.000Z*
> Health care stocks declined late Thursday, with the NYSE Health Care Index down 2.4% and the State Street Health Care Se

### [Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness](https://longbridge.com/zh-CN/news/277983333.md)
*2026-03-05T20:25:21.000Z*
> Analyst Serge Belanger of Needham has maintained a Buy rating on Cormedix, lowering the price target to $14.00. He belie

### [CorMedix nears an 11-month low after earnings miss](https://longbridge.com/zh-CN/news/277964737.md)
*2026-03-05T16:15:16.000Z*
> CorMedix (CRMD) shares fell ~12% to an 11-month low after missing Q4 2025 earnings forecasts, reporting $0.16 EPS agains